The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing ...
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
